Evidence map›Paper›PMID 34968525›Full record

ReviewNeuroscience and biobehavioral reviews2022

Nicotine and opioid co-dependence: Findings from bench research to clinical trials.

Lilian Custodio, Samantha Malone, Michael T Bardo, Jill R Turner

Open access · greenAbstract readReview
In one paragraph

Review in Neuroscience and biobehavioral reviews, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Disrupted brain state dynamics in opioid and alcohol use disorder: attenuation by nicotine use.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Lilian CustodioDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA.
Samantha MaloneDepartment of Psychology, University of Kentucky, Lexington, KY, USA.
Michael T BardoDepartment of Psychology, University of Kentucky, Lexington, KY, USA.
Jill R TurnerDepartment of Pharmaceutical Sciences, University of Kentucky, Lexington, KY, USA. Electronic address: Jill.turner@uky.edu.
University of Kentucky · US

Funding

Research Training in Drug Abuse BehaviorT32DA035200 · NIDA · UNIVERSITY OF KENTUCKY · PI CRAIG R RUSH, William Walton Stoops · 2013 to 2026
$4.4M
Functional and Genomic Signatures of Escalated Fentanyl UseR01DA053070 · NIDA · UNIVERSITY OF KENTUCKY · PI BARDO, MICHAEL T, ORTINSKI, PAVEL IVANOVICH · 2021 to 2025
$3.2M
Dynamic Signaling of NRG3-ErbB4 in the Hippocampus Mediates Nicotine Withdrawal PhenotypesR01DA044311 · NIDA · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI TURNER, JILL R. · 2018 to 2022
$1.9M
NIDA NIH HHS R01 DA044311NIDA NIH HHS R01 DA053070NIDA NIH HHS T32 DA035200
6 · The paper itself

Abstract

Concomitant use of tobacco and opioids represents a growing public health concern. In fact, the mortality rate due to smoking-related illness approaches 50% among SUD patients. Cumulative evidence demonstrates that the vulnerability to drugs of abuse is influenced by behavioral, environmental, and genetic factors. This review explores the contribution of genetics and neural mechanisms influencing nicotine and opioid reward, respiration, and antinociception, emphasizing the interaction of cholinergic and opioid receptor systems. Despite the substantial evidence demonstrating nicotine-opioid interactions within the brain and on behavior, the currently available pharmacotherapies targeting these systems have shown limited efficacy for smoking cessation on opioid-maintained smokers. Thus, further studies designed to identify novel targets modulating both nicotinic and opioid receptor systems may lead to more efficacious approaches for co-morbid nicotine dependence and opioid use disorder.

Indexed as

Opioid-Related DisordersReceptors, NicotinicTobacco Use DisorderAnalgesics, OpioidHumansNicotineAnalgesics, OpioidNicotineReceptors, NicotinicClinical trialsGeneticsNeurobiology of addictionNicotineOpioidsPolydrug abuseRodent modelsSubstance use disorder

Identifiers

PMID34968525
PMCPMC10986295
OpenAlexW4200187680

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.